Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Tentative Approval for Faster-Acting Hepatitis C Drug


New York Times (10.25.2013)

All 15 members of the US Food and Drug Administration’s (FDA) panel of virus experts voted unanimously to recommend approval of drug manufacturer Gilead’s pill sofosbuvir, which treats several forms of hepatitis C virus (HCV). While not required to follow the panel’s recommendations, the FDA often does. Currently available HCV treatments can take up to a year of therapy and cure only three out of four patients. When taken daily, sofosbuvir can cure up to 90 percent of individuals infected with the most common form of HCV in just 12 weeks. The FDA is expected to make a decision on the drug by December 8.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in October 28, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.